Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced results from two arms of a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL). These data were presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. ADCETRIS is not approved for use in the front-line treatment of MTCL.

Cook Medical’s Zilver® PTX® Earns FDA Approval As First Drug-Eluting Stent in U.S. to Treat Peripheral Arterial Disease

Cook Medical has received U.S. Food and Drug Administration (FDA) marketing approval for the first devices in its Zilver® PTX® Drug-Eluting Peripheral Stent portfolio, company officials reported today. It’s the first time the FDA has approved a drug-eluting stent to treat blockages in a peripheral artery.

Eppendorf Announces New Brunswick CelliGen® BLU cabinet / 50L CelliGen® BLU vessel

Eppendorf is proud to announce the release of the next generation New Brunswick CelliGen® BLU cabinet and the much anticipated 50L CelliGen® BLU single-use vessel. The New Brunswick CelliGen® BLU system combines the trusted performance of traditional bioprocess control with all the benefits of single-use technology. Featuring interchangeable pitched-blade, single-use vessels in 5, 14 and 50 L capacities, along with the first single-use vessel to feature New Brunswick’s proprietary packed-bed impeller, the CelliGen® BLU portfolio boasts the widest range of rigid-walled, stirred-tank, single-use vessels on the market today. The next generation cabinet has taken the term flexibility to new heights. Interchangeable gas flow options, traditional and optical pH probe technology, and an integrated scale interface are just a few of the features that allow the New Brunswick CelliGen® BLU to meet today’s vast range of process needs, making it the ideal choice for high density cell culture process from research through production.

Western Union Unveils New Education Initiative around UEFA Europa League to Deliver One Million School Days

The Western Union Company (NYSE:WU), a leader in global payment services and new Global Partner of the UEFA Europa League, and the Western Union Foundation, today announced they will turn every successful pass in this season’s competition into funding to support one day’s education for young people around the world.

Hines Releases Inaugural Sustainability Report

Hines, the privately held international real estate firm, announced today the release of the firm’s first ever Sustainability Report. The comprehensive report provides a detailed review of Hines’ environmental, social and governance performance, compiled in accordance with the Global Reporting Initiative (GRI).

Gillette Fields Team for the London 2012 Olympic Games

Gillette, a P&G brand, today introduced a team of 24 world-class athletes from 18 countries that will represent the world’s leading male grooming brand at the 2012 Olympic Games in London. The athletes include Roger Federer of Switzerland, Ryan Lochte of the United States, Lin Dan of China, Emmanuel Ginobili of Argentina and Sir Chris Hoy of Great Britain. Each of these athletes will participate in activities to help inspire and encourage future generations to achieve greatness through great starts in athletics – and in life.